RCS - Ondine Biomedical - Steriwave in first Swiss hospital

Ondine BiomedicalAnnouncement

08/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250408:nRSH0140Ea&default-theme=true

RNS Number : 0140E  Ondine Biomedical Inc.  08 April 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Switzerland's University Hospital Zurich undertakes independent research study
on Steriwave for preoperative nasal decolonization

Ondine Biomedical Inc. (LON: OBI) reports that University Hospital Zurich
(USZ) has initiated an independent clinical study evaluating Steriwave(®).
This marks the first Swiss deployment of Ondine's nasal decolonization
technology to combat surgical site infections (SSI).

The study, titled "Preoperative Microbial Reduction of the Nasal Cavity with
Antimicrobial Photodynamic Therapy (aPDT)," is led by Professor Dr. Harald
Essig, Head of the Department of Cranio-Maxillo-Facial and Oral Surgery at
USZ. This research will assess the efficacy of Steriwave in rapidly reducing
preoperative nasal microbial burden - a key factor in SSI rates and hospital
length of stay.

"Reducing post-surgical infections remains a top priority in
Cranio-Maxillo-Facial and Oral Surgery, particularly in high-risk procedures,"
said Dr. Essig. "This study allows us to evaluate a novel, fast-acting
approach to nasal decolonization that could represent a meaningful advancement
in infection prevention."

Steriwave antimicrobial photodynamic therapy is a light-activated
antimicrobial with ultra-fast efficacy that destroys a broad spectrum of
pathogens, including antibiotic-resistant strains. This innovative technology
is used to sanitize the nasal cavity, a primary reservoir for bacteria,
viruses, and fungi that can lead to SSIs and hospital-acquired infections
(HAI), particularly in high-risk surgical procedures. Unlike traditional
approaches that rely on repeat doses of topical antibiotics and take days to
take effect, Steriwave works immediately with a single, five-minute treatment,
making it an ideal solution for preoperative nasal decolonization.

The USZ study builds on extensive clinical use in Canada and the UK which have
established that Steriwave enhances patient safety as well as combatting
antimicrobial resistance.

Carolyn Cross, CEO of Ondine Biomedical, stated:

"Ondine Biomedical is proud to collaborate with the distinguished research
team at University Hospital Zurich, where there is a strong and
well-established history of researching aPDT. We appreciate their initiation
of this study, and are confident the findings will further validate
Steriwave's ability to rapidly and safely reduce pathogens associated with
HAI. Deploying Steriwave at USZ is another important step in our mission to
provide innovative, broad-spectrum solutions for infection prevention and to
address the growing global threat of antimicrobial resistance."

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          Via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Rupert Walford, Kathryn Deegan                              +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                            +44 (0)77 1000 5910

 

 

About University Hospital Zurich (USZ):

University Hospital Zurich is a leading medical center in Switzerland,
renowned for its comprehensive healthcare services and cutting-edge research,
including in the field of photodynamic therapy. The Department of
Cranio-Maxillo-Facial and Oral Surgery  at USZ specializes in the diagnosis,
surgical treatment, and rehabilitation of complex conditions involving the
facial skeleton, jaws, and oral cavity. Its clinical focus lies in restoring
both function and aesthetics through advanced reconstructive techniques,
trauma care, and oncologic surgery. In parallel, the clinic engages in
cutting-edge research on inflammatory diseases and osteomyelitis of the
craniofacial bones, with a particular emphasis on innovative treatment
approaches that operate independently of conventional antibiotic strategies
such as Photodynamic Inactivation. Further research priorities include the
development and clinical application of bioactive ceramics for bone
regeneration, the use of computer-assisted surgical procedures with
patient-specific implants, and novel strategies for the early detection and
treatment of oral and maxillofacial cancers.

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies (also known as 'photodisinfection').
Ondine has a pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

About Steriwave(®) Nasal Photodisinfection

Steriwave is an innovative antimicrobial treatment that rapidly eliminates a
broad spectrum of pathogens, including bacteria, viruses, and fungi. Using a
proprietary, light-activated antimicrobial agent, Steriwave works in a simple
two-step process: the agent is first applied to the nostrils with a nasal
swab, then activated by a specific wavelength of red light. This activation
triggers an oxidative burst that destroys pathogens within a single
five-minute treatment-providing offering a robust alternative to traditional
antibiotics without the risk of developing resistance.

 

Nasal decolonization is recommended in the 2016 WHO Global guidelines for the
prevention of surgical site infections, 1  (#_edn1) and the Society for
Healthcare Epidemiology of America (SHEA) guidelines, published in May 2023,
recommend nasal decolonization for major surgical procedures. 2  (#_edn2)

 

(#_ednref1)  1  Surgical Site Infection Prevention: Key facts on
decolonization of nasal carriers of Staphylococcus aureus. World Health
Organization. (link
(https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2)
)

(#_ednref2)  2  Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to
prevent surgical site infections in acute-care hospitals: 2022 Update. Infect
Control Hosp Epidemiol. 2023;44(5):695-720. (link
(https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/strategies-to-prevent-surgical-site-infections-in-acutecare-hospitals-2022-update/2F824B9ADD6066B29F89C8A2A127A9DC)
)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAIRMTTMTAMTRA